Okyo Pharma Ltd. (OKYO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances development of its lead ophthalmic candidate targeting neuropathic corneal pain.
What Makes OKYO Pharma (OKYO) a New Buy Stock
OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company continues advancing its clinical programs in neuropathic corneal pain and inflammatory eye diseases.
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) said on Wednesday it observed improvements in quality-of-life measures in patients treated with its experimental therapy urcosimod in a mid-stage study for neuropathic corneal pain (NCP), a chronic eye condition with no approved treatments. The clinical-stage biopharmaceutical company said the findings stem from an exploratory analysis of patient-reported outcomes in its Phase 2a trial and will be presented at the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology.
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, scheduled for May 3 to 7 in Denver, Colorado. Chief scientific officer Dr Raj Patil is set to present the findings from OKYO's Phase 2a proof-of-concept clinical trial of urcosimod, a preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity for NCP.
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
Analysts from Lucid Capital, H.C. Wainwright, and B.
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds of about $20 million. The clinical-stage biopharmaceutical company said it intends to use the net proceeds primarily to fund the clinical development of its product candidates, as well as for general corporate purposes and working capital.
OKYO Pharma appoints Flavio Mantelli as chief medical officer
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, has appointed Flavio Mantelli as its Chief Medical Officer. Dr Mantelli joins OKYO Pharma with extensive experience in ocular surface drug development, including leading the clinical development and global strategy for Oxervate at Dompé farmaceutici, which reached blockbuster status with sales exceeding $1 billion in 2024.
OKYO Pharma's neuropathic corneal pain study greenlit by FDA - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week confirmed it is set to launch a Phase 2b/3 clinical trial for neuropathic corneal pain, following a productive Type C meeting with the US Food and Drug Administration (FDA). In a conversation with Proactive, chief executive Robert Dempsey said the regulatory meeting provided "a clear line of sight" for advancing the programme, which targets a condition he described as severely debilitating and significantly underserved.
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that an abstract on its lead candidate, urcosimod, has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The abstract, titled “Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study”, will be presented in the Ocular Surface Disease II session on April 11, 2026, in Washington, DC.
OKYO Pharma reports positive FDA feedback on planned neuropathic corneal pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from the US Food and Drug Administration (FDA) following a Type C meeting on the design of its planned Phase 2b/3 clinical trial of its investigational therapeutic urcosimod for the treatment of neuropathic corneal pain (NCP). The company said the FDA agreed that the proposed primary endpoint, reduction in pain measured by the Visual Analogue Scale at Week 12, is clinically meaningful, including acknowledgment that a two-point or greater improvement on the scale represents a meaningful treatment effect.
OKYO Pharma gets FDA nod for compassionate use of eye drug in neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) said on Friday the US Food and Drug Administration has authorized a single-patient expanded access, or compassionate use, investigational new drug application for its experimental eye therapy urcosimod to treat neuropathic corneal pain. The FDA authorization allows urcosimod, at a 0.05% dose, to be used in a patient with severe neuropathic corneal pain who has limited treatment options and no FDA-approved therapies available.
